Michael T. Jaklitsch

Michael T. Jaklitsch

Auto-generated profile, based on publicly available information

Michael T. Jaklitsch

Brigham and Women's Hospital - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
Nicolò Matteo Luca BattistiNicolò Matteo Luca Battisti
Nicolò Matteo Luca Battisti
AMAnna Rachelle Mislang
Anna Rachelle Mislang
LCLisa Cooper
Lisa Cooper
AOAnita O'Donovan
Anita O'Donovan
RARiccardo A. Audisio
Riccardo A. Audisio
HWhans wildiers
hans wildiers

1 December 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
IMIsacco Montroni
Isacco Montroni
GUGiampaolo Ugolini
Giampaolo Ugolini
NSNicole M Saur
Nicole M Saur
SRSiri Rostoft
Siri Rostoft
ASAntonino Spinelli
Antonino Spinelli
SGSIOG Surgical Task Force/ESSO GOSAFE Study Group
SIOG Surgical Task Force/ESSO GOSAFE Study Group
PURPOSE: The GOSAFE study evaluates risk factors for failing to achieve good quality of life (QoL) and functional recovery (FR) in older patients undergoing surgery for colon and rectal cancer. METHODS: Patients age 70 years and older undergoing major elective colorectal surgery were prospectively enrolled. Frailty assessment was performed and outcomes, including QoL (EQ-5D-3L) recorded (3/6 months postoperatively). Postoperative FR was defined as a combination of Activity of Daily Living ≥5 + Timed Up & Go test 2. RESULTS: Prospective complete data were available for 625/646 consecutive patients (96.9%; 435 colon and 190 rectal cancer), 52.6% men, and median age was 79.0 years (IQR, 74.6-82.9 years). Surgery was minimally invasive in 73% of patients (321/435 colon; 135/190 rectum). At 3-6 months, 68.9%-70.3% patients experienced equal/better QoL (72.8%-72.9% colon, 60.1%-63.9% rectal cancer). At logistic regression analysis, preoperative Flemish Triage Risk Screening Tool ≥2 (3-month odds ratio [OR], 1.68; 95% CI, 1.04 to 2.73; P = .034, 6-month OR, 1.71; 95% CI, 1.06 to 2.75; P = .027) and postoperative complications (3-month OR, 2.03; 95% CI, 1.20 to 3.42; P = .008, 6-month OR, 2.56; 95% CI, 1.15 to 5.68; P = .02) are associated with decreased QoL after colectomy. Eastern Collaborative Oncology Group performance status (ECOG PS) ≥2 is a strong predictor of postoperative QoL decline in the rectal cancer subgroup (OR, 3.81; 95% CI, 1.45 to 9.92; P = .006). FR was reported by 254/323 (78.6%) patients with colon and 94/133 (70.6%) with rectal cancer. Charlson Age Comorbidity Index ≥7 (OR, 2.59; 95% CI, 1.26 to 5.32; P = .009), ECOG ≥2 (OR, 3.12; 95% CI, 1.36 to 7.20; P = .007 colon; OR, 4.61; 95% CI, 1.45 to 14.63; P = .009 rectal surgery), severe complications (OR, 17.33; 95% CI, 7.30 to 40.8; P < .001), fTRST ≥2 (OR, 2.71; 95% CI, 1.40 to 5.25; P = .003), and palliative surgery (OR, 4.11; 95% CI, 1.29 to 13.07; P = .017) are risk factors for not achieving FR. CONCLUSION: The majority of older patients experience good QoL and stay independent after colorectal cancer surgery. Predictors for failing to achieve these essential outcomes are now defined to guide patients' and families' preoperative counseling.

1 June 2021 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
AMAnna Rachelle Mislang
Anna Rachelle Mislang
ESEnrique Soto-Pérez-De-Celis
Enrique Soto-Pérez-De-Celis
CRChiara Russo
Chiara Russo
GCGiuseppe Ferdinando Colloca
Giuseppe Ferdinando Colloca
GWGrant Williams
Grant Williams
Nicolò Matteo Luca BattistiNicolò Matteo Luca Battisti
Nicolò Matteo Luca Battisti

1 November 2004 in Thoracic Surgery Clinics
Verified
Journal Article
Closed access
SPSubroto Paul
Subroto Paul
SNSiyamek Neragi-Miandoab
Siyamek Neragi-Miandoab
MJMichael T. Jaklitsch
Michael T. Jaklitsch

1 June 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MJM. T. Jaklitsch
M. T. Jaklitsch
LGL. Gu
L. Gu
DHD. H. Harpole
D. H. Harpole
TDTania D’Amico
Tania D’Amico
RMR. J. McKenna
R. J. McKenna
DSD. J. Sugarbaker
D. J. Sugarbaker
7065 Background: N2 nodal downstaging following neoadjuvant therapy for Stage IIIA(N2) NSCLC correlates with improved survival after lung resection. Pathologic assessment of nodes following neoadjuvant therapy may avoid unnecessary thoracotomy. Repeat mediastinoscopy has increased risk and limited efficacy. VATS may provide a safe alternative for restaging. Methods: The primary objective of this prospective multi-institutional study was to determine the feasibility of VATS restaging of ipsilateral nodes in mediastinoscopy proven stage IIIA(N2) NSCLC following 2 cycles neoadjuvant platinum-based chemotherapy (chemo) and/or ≥ 40 Gy radiotherapy (XRT) prior to thoracotomy. The goal of VATS re-staging was to biopsy 3 (-) lymph node stations, 1 (+) N2 node, or pleural carcinomatosis. Results: 70 evaluable patients (pts) were accrued from 10 institutions, 47% male, 97% white, and 71% aged between 50 and 69 years. 60% had performance status (PS) = 0, 40% PS = 1. 47 pts (67%) had XRT, 68 (97%) had chemo. Number of VATS incisions ranged from 1 to 4, median 3. Median time of VATS was 63 minutes, range from 27 to 313. VATS restaging met criteria in 40 pts (57%) and revealed: 4 pleural carcinomatosis, 17 persistent N2 disease, 19 had 3 (-) nodal stations. An additional 13 VATS (18.6%) found no evidence of persistent N2 disease, but had inadequate nodal sampling due to unanticipated obliteration of nodal tissue. Thus, 53 VATS (76%, 95% CI: 64 - 85%) were able to restage the mediastinum. VATS was unsuccessful in 17 (24%): 11 due to adhesions/fibrosis, 4 from tumor bulk preventing nodal access, 1 VATS was aborted due to airway injury, and 1 had inadequate lung deflation. Of the 53 completed VATS, 21 provided cancer tissue, and 31 had histologic tissue obtained during thoracotomy. N2 downstaging occurred in 32 pts (46%). Sensitivity of VATS was 75%, specificity was 100%, and negative predictive value was 75.8%. No deaths, but 1 airway injury was directly attributed to VATS. Conclusions: VATS restaging was feasible and provided pathologic assessment of ipsilateral nodes in treated IIIA(N2) NSCLC. New treatment paradigms can be built on pathologic restaging. No significant financial relationships to disclose.

29 January 2018 in Annual Review of Medicine
Verified
Journal Article
Closed access
FJFrancine L. Jacobson
Francine L. Jacobson
MJMichael T. Jaklitsch
Michael T. Jaklitsch
Parallel and often unrelated developments in health care and technology have all been necessary to bring about early detection of lung cancer and the opportunity to decrease mortality from lung cancer through early detection of the disease by computed tomography. Lung cancer screening programs provide education for patients and clinicians, support smoking cessation as primary prevention for lung cancer, and facilitate health care for tobacco-associated diseases, including cardiovascular and chronic lung diseases. Guidelines for lung cancer screening will need to continue to evolve as additional risk factors and screening tests are developed. Data collection from lung cancer screening programs is vital to the further development of fiscally responsible guidelines to increase detection of lung cancer, which may include small groups with elevated risk for reasons other than tobacco exposure.